Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CTFA says some cosmetic drugs should be exempt from label order-of-information regs.

This article was originally published in The Tan Sheet

Executive Summary

CTFA ADVOCATES "SPECIAL" LABEL REGS FOR COSMETIC DRUGS WITHOUT DOSE LIMITS at a Sept. 29 FDA public hearing on OTC drug labeling. CTFA Associate General Counsel James Skiles stressed that the association "fully supports" the OTC label reform proposal presented by Nonprescription Drug Manufacturers Association VP-Science and Technology William Soller, PhD, at the hearing. However, he maintained that "cosmetic drugs that do not bear dosage limitations" should be exempt from NDMA's order of information for labels, which stipulates that active ingredients should be listed first.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts